Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1806 | Hydroxychloroquine Sulfate Regular dose Wiki | 0.53 |
| drug1805 | Hydroxychloroquine Sulfate Loading Dose Wiki | 0.53 |
| drug4484 | fMRI Wiki | 0.38 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1316 | EP Wiki | 0.38 |
| drug805 | CT-scan Wiki | 0.38 |
| drug627 | Brain Health Education (BHE) Wiki | 0.38 |
| drug4814 | zinc Wiki | 0.38 |
| drug3076 | Prescription Opioid Management App Wiki | 0.38 |
| drug2850 | Pegylated Interferon-α2b Wiki | 0.38 |
| drug1645 | Goal-Oriented Attentional Self-Regulation (GOALS) Wiki | 0.38 |
| drug3159 | Pulse oximetry Wiki | 0.38 |
| drug1302 | EEG Wiki | 0.38 |
| drug1564 | Follow up Wiki | 0.27 |
| drug731 | COVID Convalescent Plasma Wiki | 0.27 |
| drug617 | Blood tests Wiki | 0.27 |
| drug4744 | standard care Wiki | 0.19 |
| drug1265 | Doxycycline Wiki | 0.17 |
| drug2029 | Ivermectin Wiki | 0.16 |
| drug2552 | Nitazoxanide Wiki | 0.10 |
| drug2981 | Placebo oral tablet Wiki | 0.07 |
| drug421 | Azithromycin Wiki | 0.06 |
| drug3728 | Standard of Care Wiki | 0.06 |
| drug1775 | Hydroxychloroquine Wiki | 0.04 |
| drug2916 | Placebo Wiki | 0.03 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D001927 | Brain Diseases NIH | 0.51 |
| D020196 | Trauma, Nervous System NIH | 0.38 |
| D058070 | Asymptomatic Diseases NIH | 0.22 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001298 | Encephalopathy HPO | 0.51 |
| HP:0002090 | Pneumonia HPO | 0.02 |
Navigate: Correlations HPO
There are 7 clinical trials
To create a protocol for treatment of Pakistani patients with SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different quinone drug dosing regimens in controlling SARS-CoV-2 infection for asymptomatic patients.
Description: Percentage of patients who become RT-PCR negative with two RT-PCR tests performed at day 6 and day 7
Measure: RT-PCR negative status Time: 6-7 daysDescription: Time to progression to next stage of SARS-CoV-2 disease severity index
Measure: Progression of symptoms Time: 7 daysDescription: Time to onset of fever (temperature greater than 100 degree F), cough, or shortness of breath (respiratory rate >22 per minute).
Measure: Development of Symptoms Time: 7 daysDescription: Drug related adverse events as determined by data safety and monitoring board (DSMB)
Measure: Adverse events Time: 7 daysThe primary objective is to determine the clinical efficacy of Chloroquine (CQ) in health care workers with moderate to high risk of exposure to COVID-19 in preventing symptomatic COVID-19 infections. Secondary endpoints will explore the efficacy of CQ in preventing any infection as defined by seroconversion to positive anti-COVID antibody status.
Description: Symptomatic illness is defined as COVID infection guidelines and confirmed with anti-COVID antibodies that will be done on serum collect at the final visit. Symptoms include fever, chills, muscle pain, cough, shortness of breath, and diarrhea.
Measure: Number of symptomatic illness in at risk healthcare workers Time: Up to 3 monthsDescription: Diagnosis is based on symptoms of COVID-19 and confirmatory anti-COVID antibodies and when available, COVID-19 PCR.
Measure: Number of healthcare workers with symptomatic COVID infections Time: Up to 3 monthsDescription: Severe illness includes worsening of symptoms.
Measure: Number of severe illness in at risk healthcare workers Time: Up to 3 monthsDescription: Confirmation with polymerase chain reaction (PCR) when available.
Measure: Number of sero-conversions in at risk healthcare workers Time: Up to 3 monthsDescription: Adverse events that are NCI-CTCAE Grade 3 or higher will be counted.
Measure: Percentage of patients with adverse events Grade 3 or higher Time: Up to 3 monthsDescription: GI intolerance to chloroquine will be documented and recorded.
Measure: Percentage of patients with GI intolerance Time: Up to 3 monthsTo treat Pakistani patients with non-life threatening symptomatic SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different chloroquine and hydroxychloroquine dosing regimens in controlling SARS-CoV-2 infection.
Description: Percentage of patients who become RT-PCR negative with two RT-PCR tests performed at day 6 and day 7
Measure: RT-PCR result Time: 6th and 7th dayDescription: Time to progression to next stage of SARS-CoV-2 disease severity index
Measure: Progression of symptoms Time: 7 daysDescription: Death
Measure: Mortality Time: 30 daysAzithromycin has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019.
Description: the number of patients with virological cure
Measure: Number of patients with virological cure Time: 6 monthsEfficacy of Ivermectin and Doxycycline in COVID-19 treatment
Description: The number of patients with improvement or mortality
Measure: The number of patients with improvement or mortality Time: 1 monthFacing the challenge of finding an efficient treatment for COVID-19, the viral pneumonia caused by the Coronavirus SARS-Cov-2, this study intended to test if Chloroquine or Hydroxychloroquine, two drugs with strong in-vitro antiviral role proven by numerous studies and with a well defined safety profile established, for efficacy in treating COVID-19 and improving an ordinal primary outcome composed by a 9-levels scale, which was recomended by the World Health Organization.
Description: Evaluation of the clinical status of patients on the 14th day after randomization defined by the 9-levels ordinal scale, with lower scores meaning better outcomes.
Measure: World Health Organization (WHO) 9-levels ordinal scale (from 0-8) Time: 14 days after randomizationDescription: Evaluation of the clinical status of patients on the 5th, 7th, 10th and 28th day after randomization defined by the 9-levels ordinal scale, with lower scores meaning better outcomes.
Measure: World Health Organization (WHO) 9-levels ordinal scale (from 0-8) Time: 5, 7, 10 and 28 days after randomizationDescription: All-cause mortality at 28 days after randomization
Measure: Mortality Time: 28 days after randomizationDescription: Number of days without need of Mechanical Ventilation at 28 days after randomization
Measure: Ventilation free days Time: 28 days after randomizationDescription: ICU Lenght of Stay on survivors at 28 days after randomization
Measure: ICU Lenght of Stay Time: 28 days after randomizationDescription: Hospital Lenght of Stay on survivors at 28 days after randomization
Measure: Hospital Lenght of Stay Time: 28 days after randomizationDescription: Acute Kidney Disease incidence measured by Kidney Disease Improving Global Outcomes (KDIGO) stage 3 sometime until the 28th day after randomization.
Measure: Acute Kidney Disease incidence Time: 28 days after randomizationDescription: Percentage of patients needing dialysis sometime until the 28th day.
Measure: Percentage of patients needing dialysis Time: 28 days after randomizationDescription: Presence of coagulopathy sometime until the 28th day (platelets < 150000 and/or INR >1.5 and/or KPTT > 35 seconds).
Measure: Coagulopathy incidence Time: 28 days after randomizationDescription: Mean of C Reactive Protein Levels on the 5th, 7th, 10th, 14th and 28th day after randomization, during period of hospitalization
Measure: Mean of C Reactive Protein Levels Time: 5, 7, 10, 14 and 28 days after randomizationDescription: Sequential Organ Failure Assessment (SOFA) scores (range, 0-24, with higher scores indicating greater organ dysfunction) on the 5th, 7th, 10th, 14th and 28th day after randomization, during period of hospitalization.
Measure: Sequential Organ Failure Assessment (SOFA) scores Time: 5, 7, 10, 14 and 28 days after randomizationDescription: Neutrophils/lymphocytes ratio on the 5th, 7th, 10th, 14th and 28th day after randomization, during period of hospitalization.
Measure: Neutrophils/lymphocytes ratio Time: 5, 7, 10, 14 and 28 days after randomizationDescription: Safety outcome: Any kind of arrhythmia identified by the attending physician at the time of the intercurrence, confirmed by an electrocardiogram (ECG), sometime until the 28th day
Measure: Arrhythmia Time: 28 days after randomizationwe want to investigate if zinc supplementation enhance the clinical efficacy of chloroquine in treatment of COVID-19.
Description: The number of patients with improvement or mortality.
Measure: Number of patients with improvement or mortality Time: 2 weeksAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports